1. Pink Sheet
  2. >>Geography
  3. >>Europe

How To Be Prepared For A Catastrophic Data Breach

Pharmaceutical companies will be directly affected by the EU’s General Data Protection Regulation because they often hold large amounts of personal health information, such as clinical trial data, and any accidental disclosure of those data will be taken very seriously by the regulatory authorities. Richard Dickinson, Jacqueline Mulryne and Zoe Walkinshaw look at what companies should be doing to limit the impact of a catastrophic data breach on their corporate reputation, the individuals affected, and the validity of the data.

DataBreach
Pharma firms need to know how to deal with a data breach • Source: Shutterstock

The EU privacy landscape underwent a seismic shift in May 2018 when the General Data Protection Regulation (GDPR) was introduced. In the post-GDPR world, all companies face tougher fines if they experience a personal data breach – up to €20m or 4% of worldwide annual turnover.

About the Authors

Richard Dickinson and Jacqueline Mulryne are partners, and Zoe Walkinshaw is an associate, at law firm Arnold & Porter.

There are also tougher obligations to report breaches, in particular those that pose a risk to people’s rights and freedoms....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 
• By Eliza Slawther

It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.

EU Tests Unified Pathway For Combined Drug/IVD Studies

 
• By Vibha Sharma

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

More from Geography

Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement

 
• By Dean Rudge

Lupin became the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster.

Post-Approval, Real-Time Monitoring Will Help Approval Standards, US FDA’s Makary Says

 
• By Sue Sutter

The FDA will use electronic health records to “get eyes” on drugs immediately after approval, Commissioner Martin Makary told the DIA 2025 Global Annual Meeting. He also wants to reduce development time with better communication and new approval pathways.

EU Tests Unified Pathway For Combined Drug/IVD Studies

 
• By Vibha Sharma

The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.